Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
NCT06188624

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Led by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Updated on 2025-04-25

150

Participants Needed

17

Research Sites

199 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers

CONDITIONS

Official Title

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Subjects voluntarily join this study, sign the informed consent form, and have good compliance
  • Age between 18 and 75 years
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Expected survival of more than 3 months
  • Histological or cytological diagnosis of advanced cancers
  • Advanced malignancies with failed standard therapy or lack of effective treatment
  • Major organs functioning well
  • Female and male subjects of childbearing potential agree to use contraception during the study and for 6 months after completion
Not Eligible

You will not qualify if you...

  • Current or previous other malignancies within 2 years before the first dose
  • Unresolved toxicity of Grade 1 or above from prior anti-tumor therapy
  • Significant surgery, biopsy, or traumatic injury within 28 days before the first dose
  • Long-term unhealed wounds or fractures
  • Cerebrovascular accident, deep vein thrombosis, or pulmonary embolism within 6 months before the first dose
  • History of psychotropic drug abuse without abstinence or mental disorders
  • Any severe and/or uncontrolled disease
  • Live attenuated vaccination within 2 weeks before the first dose or planned during the study
  • History of unexplained severe allergies or hypersensitivity to monoclonal antibodies, immunoglobulins, TQB2922, or its excipients
  • Investigator judgment of serious concomitant diseases or other reasons making the subject unsuitable for enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China, 400030

Not Yet Recruiting

2

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China, 510060

Actively Recruiting

3

The first affiliated hospital of Guangzhou medical university

Guangzhou, Guangdong, China, 510062

Not Yet Recruiting

4

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China, 150081

Not Yet Recruiting

5

Henan Cancer Hospital

Zhengzhou, Henan, China, 450003

Not Yet Recruiting

6

Henan Provincine People's Hospital

Zhengzhou, Henan, China, 450003

Not Yet Recruiting

7

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China, 450052

Not Yet Recruiting

8

The Second Xiangya Hospital of Central South University

Changsha, Hunan, China, 410011

Not Yet Recruiting

9

Hunan Cancer Hospital

Changsha, Hunan, China, 410013

Not Yet Recruiting

10

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, China, 210008

Not Yet Recruiting

11

Affiliated Zhongshan Hospital of Dalian University

Dalian, Liaoming, China, 116001

Not Yet Recruiting

12

Department of Medical Oncology, The First Hospital of China Medical University

Shenyang, Liaoning, China, 110001

Not Yet Recruiting

13

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China, 7100614

Not Yet Recruiting

14

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China, 200433

Not Yet Recruiting

15

Affiliated Hospital of North Sichuan Medical College

Nanchong, Sichuan, China, 637000

Not Yet Recruiting

16

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China, 300060

Not Yet Recruiting

17

Yunnan Cancer Hospital

Kunming, Yunnan, China, 650118

Not Yet Recruiting

Loading map...

Research Team

L

Li Zhang, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers | DecenTrialz